108 related articles for article (PubMed ID: 18031145)
1. Becaplermin.
Balfour JA; Noble S
BioDrugs; 1999 May; 11(5):359-64. PubMed ID: 18031145
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
3. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
4. [Becaplermin gel (Regranex gel)].
Senet P
Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
7. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
9. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
[TBL] [Abstract][Full Text] [Related]
10. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats.
Seveljević-Jaran D; Cuzić S; Dominis-Kramarić M; Glojnarić I; Ivetić V; Radosević S; Parnham MJ
Skin Pharmacol Physiol; 2006; 19(5):266-74. PubMed ID: 16785777
[TBL] [Abstract][Full Text] [Related]
11. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
Ghatnekar O; Persson U; Willis M; Odegaard K
Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
[TBL] [Abstract][Full Text] [Related]
15. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
Ladin D
Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
17. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
Mustoe TA; Cutler NR; Allman RM; Goode PS; Deuel TF; Prause JA; Bear M; Serdar CM; Pierce GF
Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
Steed DL
Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
Kantor J; Margolis DJ
Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
